To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

Completed · Phase 1

Conditions studied: Type 2 Diabetes

In brief

To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.

Key facts

Study ID

NCT00790153

Run by

AstraZeneca

People needed

12

Starts

2008-11-01

Expected to finish

2009-02-01

Last updated by the study team

2009-04-10

Who can join

Age: 20 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male volunteers.
• Clinically normal physical findings (incl. Electrocardiogram (ECG)) and laboratory values as judged by the investigator.
• Have a body mass index (BMI) ≥19 and ≤30

You may not qualify if…

• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
• Intake of any prescribed medicine and OTC drugs (including herbals, vitamins and minerals), except for occasional paracetamol or nasal spray for nasal congestion, within two weeks before the first administration of the investigational product.
• Daily use of nicotine containing substances.

Where it is running

• Research Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.